B4PF: Understanding Early Disease

24 months

PROGRAM TERM

Vanderbilt University Medical Center and Translational Genomics Research Institute

ORGANIZATIONS

To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis — before patients develop symptoms and prior to significant organ dysfunction. It is important to understand — at the molecular level — what triggers disease initiation and how disease develops. 


Using lung biopsy samples from patients with a family history of ILD, genomic technologies will be used to understand the drivers of early disease and the factors that contribute to disease progression. 


Jonathan Kropski, MD, Assistant Professor, Department of Medicine at Vanderbilt University Medical Center is the principal investigator of the study. Nicholas Banovich, PhD, Associate Professor at the Translational Genomics Research Institute (TGen) is a co-investigator.

Enlil Therapeutics

Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.

A Global Collaboration for PF

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.

The PRECISIONS Study

Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is a comprehensive, multicenter, and multi-investigator study.

Additional Programs